ABSTACT 27 Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea-associated illness in 28 developing countries. There is currently no vaccine licensed to prevent ETEC and the 29 development of an efficacious prophylaxis would provide an intervention with significant 30 impact. Recent studies suggested that effective protection could be achieved by inducing 31 immunity to block colonization of ETEC. Here, we evaluated the efficacy of secretory (s) IgA2 32 and dimeric (d) IgA2 of an anti-colonization factor antigen antibody, 68-61, in the Aotus 33 nancymaae non-human primate (NHP) ETEC challenge model via oral and parental delivery.
48
INTRODUCTION 49 Enterotoxigenic Escherichia coli (ETEC) is the most common cause of diarrheal illness in 50 infants in the developing world and in travelers to endemic countries. An estimated 10 million 51 cases per year occur among travelers and military personnel deployed in endemic regions [1] . 52 ETEC is a non-invasive pathogen that mediates small intestine adherence through filamentous 53 bacterial surface structures known as colonization factors (CF) . Once bound to the small 54 intestine, the bacteria produce toxins causing a net flow of water from enterocytes, leading to 55 watery diarrhea [2, 3] . Previous approaches to prevent ETEC infection have targeted bacterial 56 attachment and colonization. However, poor responses to vaccines and difficulties in the 57 establishment of protective mucosal immunity against diverse types of CFs have hindered the 58 licensing of ETEC vaccines.
In secretory IgA, two IgA monomers are covalently linked by a joining chain (J-chain), and 72 stabilized by a polypeptide called the secretory component that make the molecule more resistant 73 to digestion in the small intestine than IgG [8] . Early studies also have suggested that the 74 secretory component may have its own antimicrobial activity to block epithelial adhesion of 75 
RESULTS

91
Production and characterization of 68-61 SIgA2 and dIgA2 antibodies for NHP studies 92 Large scale production for anti-CfaE 68-61 dIgA2 and SIgA2 antibodies were set up to generate 93 sufficient material for NHP studies using an established IgA production platform in our laboratory [10] . To verify the antibody quality, purified antibodies were analyzed by SDS-PAGE 95 and western blots ( Fig. 1A ). MRHA and Caco-2 cell adhesion assays were also conducted to test 96 the antibody in vitro functionalities. Similar to what was reported previously [10], both purified 97 68-61 dIgA2 and SIgA2 showed functional activity in both hemagglutination assay (minimal 98 inhibitory concentration of 0.04ug/ml and 0.08ug/ml) and Caco-2 adhesion assay ( Fig. 1B and C, 99 respectively). (Table 2 ). There was no significant difference in the colonization rate or the duration of shedding 110 between the treatment groups. Based on the diarrheal attack rates, oral anti-CfaE SIgA2 (Group reduced the diarrheal attack rate, although the reduction did not reach significance (57.1%; 114 P=0.072) as compared to Group 3 (Table 3 ). Of note, Group 1 animals did not receive any of the 115 oral rehydration drink on days -1 and +1 that was used to orally administer the SIgA antibodies 
